key: cord-0964739-y7b6hwxz authors: Zhang, Chencheng; Zhu, Kaiwen; Li, Dianyou; Voon, Valerie; Sun, Bomin title: Deep brain stimulation telemedicine for psychiatric patients during the COVID-19 pandemic date: 2020-06-12 journal: Brain Stimul DOI: 10.1016/j.brs.2020.06.011 sha: b890ca7658ad969fa592f02e93ef8d9be228fb8a doc_id: 964739 cord_uid: y7b6hwxz nan 2 Dear Editor, 18 We read with great interest the recent paper by Caulfield and George [1] , in 19 which they discuss how at-home neurotherapeutics, including self-administered 20 repetitive transcranial magnetic stimulation and transcranial direct current 21 stimulation, could assist to manage some of the potential mental health problems, 22 particularly depression, caused by self-isolation during the COVID-19 pandemic. We 23 concur with their view, but the authors did not discuss another neurotherapeutic 24 technique that could be translated into a home setting, namely deep brain 25 stimulation (DBS). Here, we briefly describe our experiences with the application of 26 DBS telemedicine to maintain the delivery of DBS treatment and care to psychiatric 27 patients who needed to remain at home during the COVID-19 outbreak and 28 lockdown of the city of Wuhan (from 23 th January to 8 th April 2020). 29 DBS is an implantable neurosurgical treatment that has been approved for the 30 management of intractable obsessive-compulsive disorder (OCD) in many countries 31 instructions to stay at home and self-isolate, made the outpatients' regular visits to 49 the clinic not possible. This interruption of routine care could compromise their 50 mental and physical well-being. Moreover, the patients were likely to be especially 51 vulnerable to the detrimental psychological effects of social isolation, uncertainty, 52 and stress associated with the COVID-19 pandemic [1, 8] . This posed an additional 53 significant mental health threat to our patients. To address these health risks, we 54 utilized DBS telemedicine to deliver and manage the treatment and care at their own 55 Initially, we contacted all psychiatric outpatients treated with DBS to check their 57 mental and physical health status. We also assessed their clinical symptoms as 58 regularly scheduled using DBS tele-processing, synchronous real-time video 59 communications, and online self-report clinical assessment scales. One patient with 60 MDD had ran out of medications (daily dose, duloxetine 60 mg, olanzapine 5 mg, 61 clonazepam 2 mg) and requested telemedicine DBS parameter adjustment to cope 62 with recurrent depression symptoms. Not completely unexpected, DBS failed to 63 work as a substitute for pharmacotherapy. The depression symptoms were 64 eventually relieved by online prescribing of the patient's needed medications. Another patient who had received DBS surgery for OCD was unable to visit the 66 hospital for the initial post-operative DBS parameter adjustment. Consequently, DBS 67 telemedicine was employed for the initial post-operative clinical examination and 68 DBS parameter adjustment. Thereafter, the patient received additional DBS 69 tele-processing parameter refinements and psychological support for the duration of 70 one month (once a week) at home. After one month, the patient reported significant, 71 stable improvements in OCD symptoms and satisfaction with the treatment. 72 These cases illustrate that DBS telemedicine can be particularly helpful during 73 the COVID-19 pandemic to maintain the quality of health care delivery to psychiatric 74 outpatients who need to stay at home and self-isolate. However, in contrast to the 75 noninvasive at-home neurotherapeutics discussed by Caulfield and George [1] , DBS 76 telemedicine in an invasive therapeutic intervention that should only be applied to 77 severe, chronic, and medically otherwise intractable cases of MDD or other 78 psychiatric disorders. Yet, a relative advantage of DSB telemedicine is its capability to 79 target specific deep brain structures, networks, and functions, including limbic and 80 basal ganglia structures, that are believed to play a key role in the pathophysiology 81 6 and disturbances of mood and motivation that underlie MDD and certain other 82 psychiatric disorders. Notwithstanding, we fully agree with Caulfield and George that 83 the COVID-19 pandemic is underlining a growing need for the further development 84 of at-home neurotherapeutics. We think that DBS telemedicine will have a 85 significant role to play in the management of psychiatric patients who have been 86 treated with DBS in general and, specifically, of those treated patients who need to 87 stay at home and self-isolate during the COVID-19 pandemic. 88 89 Treating the Mental Health Effects of COVID-19: The 91 Need for At-Home Neurotherapeutics Is Now Deep Brain Stimulation of the Ventral Anterior Limb of the Internal Capsule for 95 Refractory Obsessive-Compulsive Disorder: A Clinical Cohort of 70 Patients. AJP 96 2020:appi.ajp.2019.1 Long 98 versus short pulse width subcallosal cingulate stimulation for treatment-resistant 99 depression: a randomised, double-blind, crossover trial Deep brain stimulation for 102 Tourette's syndrome Deep brain stimulation of the 105 8 nucleus accumbens for treatment-refractory anorexia nervosa: A long-term 106 follow-up study Neurosurgical treatment for 109 addiction: Lessons from an untold story in China and a path forward A Remote and Wireless Deep Brain 112 Neuromodulation: Technology at the Neural 113 Interface The Role 115 of This work was supported by the National Key Research and Development Program of 122 2017YFC0803607 to LDY), National Natural Science Foundation of 123 China (81771482 to BMS) and Shanghai Science and Technology Committee 18410710400 to BMS). Dr. Voon is supported by a Medical Research Council 125 We appreciate the constructive critical 126 comments of Dr Dianyou Li have received honoraria and travel expenses 130 from Medtronic, PINS, SceneRay. Dr. Bomin Sun received research support from 131 PINS and SceneRay (donated devices). The other authors have no financial conflicts 132 of interest to disclose